Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease
https://doi.org/10.14341/2072-0351-823
Abstract
Expansion of diabetic population (predominantly due to type 2 diabetes mellitus) with chronic kidney disease (CKD) comorbidity constitutes one of the major challenges in modern medicine.
Throughout the course of diabetes nephropathy development, from its debut to the terminal stage, survival rate and quality of life are lower than those of other categories of patients. This indicates crucial role of hyperglycemia in accelerated metabolic degradation typical of CKD.
Renal disease severely narrows the spectrum of available glucose-lowering agents. Concurrent treatment for hypertension and dyslipidemia, as well as anti-platelet therapy and stimulation of erythropoiesis becomes a complex issue. A creative and patient-oriented approach with clear metabolic and cardiovascular goals should be instrumental in its solution.
About the Authors
Minara Shamkhalovna Shamkhalova
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
Ivona Renata Yarek-Martynova
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
Natalya Petrovna Trubitcyna
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
References
1. Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. М: МИА: 2009. 482 с. [Shestakova MV, Dedov II. Diabetes mellitus and chronic kidney disease. Moscow: MIA: 2009. 482 p.]
2. United States Renal Data System, USRDS 2012 Annual Data Report. Available from: http://www.usrds.org/adr.aspx
3. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. The Lancet.380(9844):807-814. DOI: http://dx.doi.org/http://dx.doi.org/10.1016/S0140-6736(12)60572-8
4. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2000;35(4):S117-S131. DOI: http://dx.doi.org/10.1016/S0272-6386(00)70239-3
5. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern. Suppl. 2013; 32(1). Available from: http://kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_CKD_GL_Suppl_Table_Jan_2013.pdf
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine. 1993;329(14):977-986. DOI: http://dx.doi.org/10.1056/NEJM199309303291401
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837-853. DOI: http://dx.doi.org/http://dx.doi.org/10.1016/S0140-6736(98)07019-6
8. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2008;358(24):2560-2572. DOI: http://dx.doi.org/doi:10.1056/NEJMoa0802987
9. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study. Archives of Internal Medicine. 2011;171(21):1920-1927. DOI: http://dx.doi.org/10.1001/archinternmed.2011.537
10. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. New England Journal of Medicine. 2011;365(21):2002-2012. DOI: http://dx.doi.org/10.1056/NEJMsa1103053
11. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney International. 2008;73(9):1062-1068. DOI: http://dx.doi.org/10.1038/ki.2008.25
12. “Hemodialysis”, book edited by Suzuki H. Chapter 8, 2013.
13. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972. DOI: http://dx.doi.org/10.2337/dc06-9912
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203. DOI: http://dx.doi.org/10.2337/dc08-9025
15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379. DOI: http://dx.doi.org/10.2337/dc12-0413
16. Heaf JG, van Biesen W. Metformin and Chronic Renal Impairment: A Story of Choices and Ugly Ducklings. Clinical Diabetes. 2011;29(3):97-101. DOI: http://dx.doi.org/10.2337/diaclin.29.3.97
17. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2010(4):CD002967. DOI: http://dx.doi.org/10.1002/14651858.CD002967.pub4
18. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 Jun;34(6):1431-1437. DOI: http://dx.doi.org/10.2337/dc10-2361
19. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrology, Dialysis, Transplantation. 2010;25(7):2044-2047. DOI: http://dx.doi.org/10.1093/ndt/gfq199
20. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, et al. PPAR-gamma agonist protects podocytes from injury. Kidney International. 2007;71(12):1232-1239. DOI: http://dx.doi.org/10.1038/sj.ki.5002248
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine. 2007;356(24):2457-2471. DOI: http://dx.doi.org/10.1056/NEJMoa072761
22. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Annals of Medicine. 2012;44(4):375-393. DOI: http://dx.doi.org/10.3109/07853890.2011.560181
23. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide. British Journal of Clinical Pharmacology. 2007;64(3):317-327. DOI: http://dx.doi.org/10.1111/j.1365-2125.2007.02890.x
24. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. British Journal of Clinical Pharmacology. 2009;68(6):898-905. DOI: http://dx.doi.org/10.1111/j.1365-2125.2009.03536.x
25. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney and Blood Pressure Research. 2012;36(1):65-84. DOI: http://dx.doi.org/10.1159/000339028
26. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, obesity & metabolism. 2008;10(7):545-555. DOI: http://dx.doi.org/10.1111/j.1463-1326.2008.00914.x
27. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes, obesity & metabolism. 2012;14(11):1032-1039. DOI: http://dx.doi.org/10.1111/j.1463-1326.2012.01634.x
28. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes, obesity & metabolism. 2011;13(6):523-532. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01382.x
29. McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237-244. DOI: http://dx.doi.org/10.2337/dc12-0706
Review
For citations:
Shamkhalova M.Sh., Yarek-Martynova I.R., Trubitcyna N.P., Shestakova M.V. Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. Diabetes mellitus. 2013;16(3):97-102. (In Russ.) https://doi.org/10.14341/2072-0351-823
Views:
4547
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
